209 related articles for article (PubMed ID: 31315653)
1. Hyperinsulinemia promotes aberrant histone acetylation in triple-negative breast cancer.
Senapati P; Kato H; Lee M; Leung A; Thai C; Sanchez A; Gallagher EJ; LeRoith D; Seewaldt VL; Ann DK; Schones DE
Epigenetics Chromatin; 2019 Jul; 12(1):44. PubMed ID: 31315653
[TBL] [Abstract][Full Text] [Related]
2. ETNPPL modulates hyperinsulinemia-induced insulin resistance through the SIK1/ROS-mediated inactivation of the PI3K/AKT signaling pathway in hepatocytes.
Chen X; Liu P; Zhang W; Li X; Wang C; Han F; Liu W; Huang Y; Li M; Li Y; Sun X; Fan X; Li W; Xiong Y; Qian L
J Cell Physiol; 2023 May; 238(5):1046-1062. PubMed ID: 36924049
[TBL] [Abstract][Full Text] [Related]
3. Hsa_circ_0000199 facilitates chemo-tolerance of triple-negative breast cancer by interfering with miR-206/613-led PI3K/Akt/mTOR signaling.
Li H; Xu W; Xia Z; Liu W; Pan G; Ding J; Li J; Wang J; Xie X; Jiang D
Aging (Albany NY); 2021 Jan; 13(3):4522-4551. PubMed ID: 33495420
[TBL] [Abstract][Full Text] [Related]
4. Targeting the PI3K/AKT/mTOR pathway in triple-negative breast cancer: a review.
Costa RLB; Han HS; Gradishar WJ
Breast Cancer Res Treat; 2018 Jun; 169(3):397-406. PubMed ID: 29417298
[TBL] [Abstract][Full Text] [Related]
5. Silence of α1-Antitrypsin Inhibits Migration and Proliferation of Triple Negative Breast Cancer Cells.
Zhao Z; Ma J; Mao Y; Dong L; Li S; Zhang Y
Med Sci Monit; 2018 Sep; 24():6851-6860. PubMed ID: 30260937
[TBL] [Abstract][Full Text] [Related]
6. Inhibiting PI3K reduces mammary tumor growth and induces hyperglycemia in a mouse model of insulin resistance and hyperinsulinemia.
Gallagher EJ; Fierz Y; Vijayakumar A; Haddad N; Yakar S; LeRoith D
Oncogene; 2012 Jul; 31(27):3213-22. PubMed ID: 22037215
[TBL] [Abstract][Full Text] [Related]
7. Histone H3 lysine 4 monomethylation (H3K4me1) and H3 lysine 9 monomethylation (H3K9me1): distribution and their association in regulating gene expression under hyperglycaemic/hyperinsulinemic conditions in 3T3 cells.
Gupta J; Kumar S; Li J; Krishna Murthy Karuturi R; Tikoo K
Biochimie; 2012 Dec; 94(12):2656-64. PubMed ID: 22951486
[TBL] [Abstract][Full Text] [Related]
8. Doubling down on the PI3K-AKT-mTOR pathway enhances the antitumor efficacy of PARP inhibitor in triple negative breast cancer model beyond BRCA-ness.
De P; Sun Y; Carlson JH; Friedman LS; Leyland-Jones BR; Dey N
Neoplasia; 2014 Jan; 16(1):43-72. PubMed ID: 24563619
[TBL] [Abstract][Full Text] [Related]
9. Rhizoma Amorphophalli inhibits TNBC cell proliferation, migration, invasion and metastasis through the PI3K/Akt/mTOR pathway.
Wu C; Qiu S; Liu P; Ge Y; Gao X
J Ethnopharmacol; 2018 Jan; 211():89-100. PubMed ID: 28962890
[TBL] [Abstract][Full Text] [Related]
10. KAT6A Acetylation of SMAD3 Regulates Myeloid-Derived Suppressor Cell Recruitment, Metastasis, and Immunotherapy in Triple-Negative Breast Cancer.
Yu B; Luo F; Sun B; Liu W; Shi Q; Cheng SY; Chen C; Chen G; Li Y; Feng H
Adv Sci (Weinh); 2021 Oct; 8(20):e2100014. PubMed ID: 34392614
[TBL] [Abstract][Full Text] [Related]
11. Combination of SF1126 and gefitinib induces apoptosis of triple-negative breast cancer cells through the PI3K/AKT-mTOR pathway.
Deng M; Wang J; Chen Y; Zhang L; Liu D
Anticancer Drugs; 2015 Apr; 26(4):422-7. PubMed ID: 25588160
[TBL] [Abstract][Full Text] [Related]
12. The PI3K/mTOR dual inhibitor NVP-BEZ235 stimulates mutant p53 degradation to exert anti-tumor effects on triple-negative breast cancer cells.
Cai J; Xia J; Zou J; Wang Q; Ma Q; Sun R; Liao H; Xu L; Wang D; Guo X
FEBS Open Bio; 2020 Apr; 10(4):535-545. PubMed ID: 32027103
[TBL] [Abstract][Full Text] [Related]
13. Combination of PI3K and MEK inhibitors yields durable remission in PDX models of PIK3CA-mutated metaplastic breast cancers.
Coussy F; El Botty R; Lavigne M; Gu C; Fuhrmann L; Briaux A; de Koning L; Dahmani A; Montaudon E; Morisset L; Huguet L; Sourd L; Painsec P; Chateau-Joubert S; Larcher T; Vacher S; Melaabi S; Salomon AV; Marangoni E; Bieche I
J Hematol Oncol; 2020 Feb; 13(1):13. PubMed ID: 32087759
[TBL] [Abstract][Full Text] [Related]
14. Targeting SET to restore PP2A activity disrupts an oncogenic CIP2A-feedforward loop and impairs triple negative breast cancer progression.
Liu CY; Huang TT; Chen YT; Chen JL; Chu PY; Huang CT; Wang WL; Lau KY; Dai MS; Shiau CW; Tseng LM
EBioMedicine; 2019 Feb; 40():263-275. PubMed ID: 30651219
[TBL] [Abstract][Full Text] [Related]
15. Depletion of histone deacetylase 3 antagonizes PI3K-mediated overgrowth of Drosophila organs through the acetylation of histone H4 at lysine 16.
Lv WW; Wei HM; Wang DL; Ni JQ; Sun FL
J Cell Sci; 2012 Nov; 125(Pt 22):5369-78. PubMed ID: 22956542
[TBL] [Abstract][Full Text] [Related]
16. The yeast AMPK homolog SNF1 regulates acetyl coenzyme A homeostasis and histone acetylation.
Zhang M; Galdieri L; Vancura A
Mol Cell Biol; 2013 Dec; 33(23):4701-17. PubMed ID: 24081331
[TBL] [Abstract][Full Text] [Related]
17. The pan-PI3K inhibitor GDC-0941 activates canonical WNT signaling to confer resistance in TNBC cells: resistance reversal with WNT inhibitor.
Tzeng HE; Yang L; Chen K; Wang Y; Liu YR; Pan SL; Gaur S; Hu S; Yen Y
Oncotarget; 2015 May; 6(13):11061-73. PubMed ID: 25857298
[TBL] [Abstract][Full Text] [Related]
18. Histone Butyrylation/ Acetylation Remains Unchanged in Triple Negative Breast Cancer Cells after a Long Term Metabolic Reprogramming.
Mehdikhani F; Ghahremani H; Nabati S; Tahmouri H; Sirati-Sabet M; Salami S
Asian Pac J Cancer Prev; 2019 Dec; 20(12):3597-3601. PubMed ID: 31870099
[TBL] [Abstract][Full Text] [Related]
19. Piperlongumine, an alkaloid causes inhibition of PI3 K/Akt/mTOR signaling axis to induce caspase-dependent apoptosis in human triple-negative breast cancer cells.
Shrivastava S; Kulkarni P; Thummuri D; Jeengar MK; Naidu VG; Alvala M; Redddy GB; Ramakrishna S
Apoptosis; 2014 Jul; 19(7):1148-64. PubMed ID: 24729100
[TBL] [Abstract][Full Text] [Related]
20. Insulin-dependent transcriptional control in L6 rat myotubes is associated with modulation of histone acetylation and accumulation of the histone variant H2A.Z in the proximity of the transcriptional start site.
Zerzaihi O; Chriett S; Vidal H; Pirola L
Biochem Cell Biol; 2014 Feb; 92(1):61-7. PubMed ID: 24471919
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]